P005 Regulators of the guanylate cyclase pathway are potential novel markers of mucosal healing in IBD

Research output: Contribution to journalAbstract

Standard

P005 Regulators of the guanylate cyclase pathway are potential novel markers of mucosal healing in IBD. / Jeffery, L E; Shivaji, U N; Zardo, D; Acharjee, A; Nardone, O M; Smith, S C; Gkoutos, G; Visweswariah, S S; Ghosh, S; Iacucci, M.

In: Journal of Crohn's & Colitis, Vol. 14, No. Supplement_1, 15.01.2020, p. S131–S132.

Research output: Contribution to journalAbstract

Harvard

APA

Vancouver

Author

Jeffery, L E ; Shivaji, U N ; Zardo, D ; Acharjee, A ; Nardone, O M ; Smith, S C ; Gkoutos, G ; Visweswariah, S S ; Ghosh, S ; Iacucci, M. / P005 Regulators of the guanylate cyclase pathway are potential novel markers of mucosal healing in IBD. In: Journal of Crohn's & Colitis. 2020 ; Vol. 14, No. Supplement_1. pp. S131–S132.

Bibtex

@article{8fb07d01e558493d8a589a52093ae517,
title = "P005 Regulators of the guanylate cyclase pathway are potential novel markers of mucosal healing in IBD",
abstract = "Background: Intestinal guanylate cyclase C (GC-C) present in epithelial cells has been shown to have a role in gut homeostasis. The downstream effects of activation of GC-C are due to production of cyclic-GMP. GC-C is encoded by the gene GUCY2C, mutations in which are implicated in Familial Diarrhoea Syndrome and noted as risk factors for Crohn{\textquoteright}s disease. GUCY2C and its activator, GUCA2A have been shown to be downregulated in IBD. We hypothesised that regulation of this pathway might be important in remission and response to therapy.Methods: Forty-four patients with IBD and 7 patients with polyps (controls) at University Hospitals Birmingham, UK were recruited under ethical consent. Relevant demographic and clinical data were extracted from the hospital EMR. All patients had disease activity recorded on endoscopic examination of mucosa and intestinal biopsies collected for analysis. Mucosal healing was defined as MES = 0 (UC) and SES-CD <6 (CD). Of 44 patients, 14 had matched baseline and 12-week post-biologic therapy assessment and had tissues collected. Intestinal biopsies were analysed by 3{\textquoteright}RNA-sequencing using the Illumina Nextseq sequencer. FASTQ files were generated through BaseSpace and reads de-multiplexed, trimmed, aligned, and quantified using the GeneGlobe (Qiagen) workflow. Expression was compared between groups using either Wilcoxon tests or Kruskal–Wallis with Dunn post-hoc analysis as appropriate.Results: Expression of Guanylate cyclase activators GUCA2A and GUCA2B in patients who showed mucosal healing was equivalent to controls, but GUCA2A was down-regulated in those with active disease (non-healing) (p = 0.006). The same pattern was observed for transcriptional regulators of GUCY2C, including HNF4A (p = 0.0248) and CDX2 (0.0062). Correspondingly, GUCY2C was reduced in non-healing mucosa, although the difference was not significant (Figure 1). In patients who responded to biologic therapy, both GUCA2A (p = 0.0234) and GUCA2B (p = 0.0117) were increased at follow-up but no change was observed for those who did not respond. Change in GUCY2C expression did not reach statistical significance in either group, although an increase was observed for a large proportion of responders.Conclusion: Our findings suggest that regulation of the Guanylate Cyclase pathway may be involved in the restoration of a stable mucosa in IBD and that expression of its regulators may be used to indicate response to treatment.",
author = "Jeffery, {L E} and Shivaji, {U N} and D Zardo and A Acharjee and Nardone, {O M} and Smith, {S C} and G Gkoutos and Visweswariah, {S S} and S Ghosh and M Iacucci",
year = "2020",
month = jan,
day = "15",
doi = "10.1093/ecco-jcc/jjz203.134",
language = "English",
volume = "14",
pages = "S131–S132",
journal = "Journal of Crohn's & Colitis",
issn = "1873-9946",
publisher = "Oxford University Press",
number = "Supplement_1",

}

RIS

TY - JOUR

T1 - P005 Regulators of the guanylate cyclase pathway are potential novel markers of mucosal healing in IBD

AU - Jeffery, L E

AU - Shivaji, U N

AU - Zardo, D

AU - Acharjee, A

AU - Nardone, O M

AU - Smith, S C

AU - Gkoutos, G

AU - Visweswariah, S S

AU - Ghosh, S

AU - Iacucci, M

PY - 2020/1/15

Y1 - 2020/1/15

N2 - Background: Intestinal guanylate cyclase C (GC-C) present in epithelial cells has been shown to have a role in gut homeostasis. The downstream effects of activation of GC-C are due to production of cyclic-GMP. GC-C is encoded by the gene GUCY2C, mutations in which are implicated in Familial Diarrhoea Syndrome and noted as risk factors for Crohn’s disease. GUCY2C and its activator, GUCA2A have been shown to be downregulated in IBD. We hypothesised that regulation of this pathway might be important in remission and response to therapy.Methods: Forty-four patients with IBD and 7 patients with polyps (controls) at University Hospitals Birmingham, UK were recruited under ethical consent. Relevant demographic and clinical data were extracted from the hospital EMR. All patients had disease activity recorded on endoscopic examination of mucosa and intestinal biopsies collected for analysis. Mucosal healing was defined as MES = 0 (UC) and SES-CD <6 (CD). Of 44 patients, 14 had matched baseline and 12-week post-biologic therapy assessment and had tissues collected. Intestinal biopsies were analysed by 3’RNA-sequencing using the Illumina Nextseq sequencer. FASTQ files were generated through BaseSpace and reads de-multiplexed, trimmed, aligned, and quantified using the GeneGlobe (Qiagen) workflow. Expression was compared between groups using either Wilcoxon tests or Kruskal–Wallis with Dunn post-hoc analysis as appropriate.Results: Expression of Guanylate cyclase activators GUCA2A and GUCA2B in patients who showed mucosal healing was equivalent to controls, but GUCA2A was down-regulated in those with active disease (non-healing) (p = 0.006). The same pattern was observed for transcriptional regulators of GUCY2C, including HNF4A (p = 0.0248) and CDX2 (0.0062). Correspondingly, GUCY2C was reduced in non-healing mucosa, although the difference was not significant (Figure 1). In patients who responded to biologic therapy, both GUCA2A (p = 0.0234) and GUCA2B (p = 0.0117) were increased at follow-up but no change was observed for those who did not respond. Change in GUCY2C expression did not reach statistical significance in either group, although an increase was observed for a large proportion of responders.Conclusion: Our findings suggest that regulation of the Guanylate Cyclase pathway may be involved in the restoration of a stable mucosa in IBD and that expression of its regulators may be used to indicate response to treatment.

AB - Background: Intestinal guanylate cyclase C (GC-C) present in epithelial cells has been shown to have a role in gut homeostasis. The downstream effects of activation of GC-C are due to production of cyclic-GMP. GC-C is encoded by the gene GUCY2C, mutations in which are implicated in Familial Diarrhoea Syndrome and noted as risk factors for Crohn’s disease. GUCY2C and its activator, GUCA2A have been shown to be downregulated in IBD. We hypothesised that regulation of this pathway might be important in remission and response to therapy.Methods: Forty-four patients with IBD and 7 patients with polyps (controls) at University Hospitals Birmingham, UK were recruited under ethical consent. Relevant demographic and clinical data were extracted from the hospital EMR. All patients had disease activity recorded on endoscopic examination of mucosa and intestinal biopsies collected for analysis. Mucosal healing was defined as MES = 0 (UC) and SES-CD <6 (CD). Of 44 patients, 14 had matched baseline and 12-week post-biologic therapy assessment and had tissues collected. Intestinal biopsies were analysed by 3’RNA-sequencing using the Illumina Nextseq sequencer. FASTQ files were generated through BaseSpace and reads de-multiplexed, trimmed, aligned, and quantified using the GeneGlobe (Qiagen) workflow. Expression was compared between groups using either Wilcoxon tests or Kruskal–Wallis with Dunn post-hoc analysis as appropriate.Results: Expression of Guanylate cyclase activators GUCA2A and GUCA2B in patients who showed mucosal healing was equivalent to controls, but GUCA2A was down-regulated in those with active disease (non-healing) (p = 0.006). The same pattern was observed for transcriptional regulators of GUCY2C, including HNF4A (p = 0.0248) and CDX2 (0.0062). Correspondingly, GUCY2C was reduced in non-healing mucosa, although the difference was not significant (Figure 1). In patients who responded to biologic therapy, both GUCA2A (p = 0.0234) and GUCA2B (p = 0.0117) were increased at follow-up but no change was observed for those who did not respond. Change in GUCY2C expression did not reach statistical significance in either group, although an increase was observed for a large proportion of responders.Conclusion: Our findings suggest that regulation of the Guanylate Cyclase pathway may be involved in the restoration of a stable mucosa in IBD and that expression of its regulators may be used to indicate response to treatment.

U2 - 10.1093/ecco-jcc/jjz203.134

DO - 10.1093/ecco-jcc/jjz203.134

M3 - Abstract

VL - 14

SP - S131–S132

JO - Journal of Crohn's & Colitis

JF - Journal of Crohn's & Colitis

SN - 1873-9946

IS - Supplement_1

ER -